Pasithea Therapeutics Corp. Quarterly report [Sections 13 or 15(d)]

Intangible Assets

3 Months Ended

Mar. 31, 2026

NOTE 3 – INTANGIBLE ASSETS

Intangible assets, net consists of the following (in thousands):

Intangible Assets

	March 31, 2026							December 31, 2025
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Impairment			Net
In-process research and development	$	-	$	-		$	-	$	2,900,000	$	-		$	(2,900,000	)	$	-
Patents and intellectual property		5,671,478		(2,048,033	)		3,623,445		5,671,478		(1,890,492	)					3,780,986
Intangible assets, net	$	5,671,478	$	(2,048,033	)	$	3,623,445	$	8,571,478	$	(1,890,492	)				$	3,780,986

As of March 31, 2026, future expected amortization expense of Intangible assets was as follows:

2026 (remaining)	$	472,623
2027		630,164
2028		630,164
2029		630,164
2030		630,164
Thereafter		630,166
Remaining future amortization expense	$	3,623,445